Algen Biotechnologies
YC W20San Francisco, US · Founded 2018 · 15 employees · 2 known investors
Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesAI-powered Drug DiscoveryArtificial IntelligenceCRISPRin /company@ycombinator
Founders & leadership· Y Combinator alumni (W20)
Investors · 2
In the news
- Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discoverymanilatimes.net · 2025
- AstraZeneca Taps AI & CRISPR in $555M Play to Unlock Immunology Targets - Healthcare Leadership, Policy & Digital Health News Indiahealthbuzz.in · 2025
- AstraZeneca, Algen Biotechnologies pen $555M AI pactfiercebiotech.com · 2025
- J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United AlSaqer Group Announce Finalists of the 2024 Life Sciences Innovation Summit in Abu Dhabiprnewswire.com · 2024
- Algen Biotechnologies - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021